Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

Biosimilars to Denosumab Approved with an Interchangeable Designation

Michele B. Kaufman, PharmD, BCGP  |  April 18, 2024

The FDA has approved the first interchangeable biosimilars for denosumab.

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabdenosumab-bbdzJubbontiProliaWyostXgeva

A Delicate Balance: How to Avoid Overmedicalization in Rheumatology

Jason Liebowitz, MD, FACR  |  April 9, 2024

Rheumatologist Rachelle Buchbinder, AO, MBBS (Hons), MSc, PhD, discusses reducing overdiagnosis, overtreatment, low-value care and waste in medicine.

Filed under:EthicsProfiles Tagged with:overmedicalizationpatient care

FDA Issues Boxed Warning for Denosumab & Approves a Generic NSAID

Michele B. Kaufman, PharmD, BCGP  |  February 27, 2024

In January, the U.S. Food & Drug Administration approved indomethacin in an oral suspension, a generic version of Indocin Oral Suspension. The agency also issued a boxed warning and updated label for denosumab, warning of the risks of severe hypocalcemia in patients with chronic kidney disease.

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabDrug SafetyFDA approvalOsteoporosisU.S. Food and Drug Administration (FDA)

To the Bone: Experts Discuss Developments in Osteoporosis Care

Thomas R. Collins  |  January 29, 2024

During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D.

Filed under:ACR ConvergenceConditionsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2023denosumabOsteoporosisVitamin D

More Than Meets the Eye

Jason Liebowitz, MD, FACR  |  November 21, 2023

SAN DIEGO—In recent years, the recognition of nr-axSpa has helped identify the cause of back pain in many patients previously without a diagnosis. However, questions remain about how to avoid under- or over-diagnosing the condition. In the session titled, Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis, several speakers provided high-yield insights on this topic. Diagnostic challenges, imaging options and mimics to watch for were among the specific points of discussion.

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2023ACR Convergence 2023 PsAAS Resource Center

The 2023 ACR Awards of Distinction

Patrice Fusillo  |  November 13, 2023

SAN DIEGO—During ACR Convergence 2023 on Nov. 11, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2023 Awards of Distinction, as well as the 2023 ACR Masters who were recognized for their contributions to the field.

Filed under:ACR ConvergenceAwardsCareerMeeting Reports Tagged with:ACR Convergence 2023

Concerning the Back: Updates in AS & nr-axSpA

Jason Liebowitz, MD, FACR  |  November 2, 2023

During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.

Filed under:Axial SpondyloarthritisConditionsMeeting Reports Tagged with:AS Resource Centerdisease managementnon-radiographic axial spondyloarthritis

Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri

Jason Liebowitz, MD, FACR  |  November 1, 2023

At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:glucocorticoidHydroxychloroquine (HCQ)

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

Ruth Jessen Hickman, MD  |  October 10, 2023

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesGlucocorticoid-Induced Osteoporosis

Case Report: Giant Cell Arteritis-Related Stroke

Jessica Meek, MD, Anna Coppinger, DO, & Sejal Khan, DO  |  September 10, 2023

Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

Filed under:ConditionsHome SliderVasculitis Tagged with:case reportGCAgiant cell arteritis (GCA)stroke

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 43
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences